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Résumé 
 
Dans l’évaluation des réponses vaccinales, la détermination de l’affinité/avidité des 
anticorps pourrait renseigner sur la maturation des réponses lymphocytaires B, chez des 
sujets sains ou immunodéficients. L’objectif de ce travail a été de développer un test de 
mesure de l’avidité des anticorps plasmatiques IgG1 contre le tétanos toxoïde (TT), basé 
sur l’utilisation d’un agent chaotropique (isothiocyanate), et de l’appliquer à 90 serums 
d’enfants en bonne santé. Après optimisation, ce test s’est révêlé relativement simple et 
très fiable. Il a permis de mettre en évidence une augmentation progressive de l’avidité 
des anticorps anti-TT en fonction de l’âge, avec une correlation significative entre index 
d’avidité et log10(âge). Cette augmentation de l’avidité, qui atteint un plateau seulement 
vers 5 ans, reflète une augmentation progressive du pourcentage des anticorps de haute 
avidité et une diminution de ceux de faible avidité. Aucune corrélation n’a été relevée 
entre l’avidité et le taux plasmatique des anticorps anti-TT. 
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Introduction 
Le système immunitaire défend l’hôte contre des pathogènes tels que des 
bactéries, des virus, des champignons et des parasites. Quand l’agent infectieux n’est pas 
éradiqué rapidement par les mécanismes de l’immunité innée, c’est l’immunité adaptive 
qui entre en jeu avec ses deux composantes, l’immunité cellulaire et l’immunité 
humorale. Celle-ci agit par le biais des anticorps, des glycoprotéines produites par les 
lymphocytes B capables de lier les pathogènes (ou leurs produits) de manière hautement 
spécifique et de neutraliser leurs effets potentiellement nocifs sur l’organisme et/ou de les 
marquer afin de mettre en route leur destruction. Chaque lymphocyte B produit des 
anticorps ayant tous la même spécificité pour l’antigène. Puisqu’il existe une immense 
variabilité de structures au niveau des pathogènes, deux mécanismes principaux 
augmentent de manière très puissante le rapport variabilité des anticorps/espace utilisé sur 
le génome pour le codage des anticorps. Le premier mécanisme est celui de la diversité 
combinatoire, c’est-à-dire une diversification créée par la subdivision des gènes codant 
pour les anticorps en diverses pièces au niveau du génome, pour chacune desquelles il 
existe plusieurs variantes et qui, par un mécanisme précisément contrôlé, sont jointes 
l’une à l’autre par recombinaison au niveau de l’ADN des lymphocytes B, afin que 
chacun produise un certain type d’anticorps. Ceci a lieu durant le développement des 
lymphocytes B, c’est-à-dire avant une éventuelle réponse immunitaire à une infection. Le 
deuxième principe est celui de l’hypermutation somatique des gènes codant pour les 
anticorps, suivie d’une sélection des cellules produisant les anticorps antigène-spécifiques 
les plus avides. Ce dernier mécanisme a lieu dans les centres germinatifs des organes 
lymphoides secondaires, rate et ganglions lymphatiques. 
Réponse immunitaire humorale 
Après l’infection d’un tissu périphérique, l’antigène est transporté vers les tissus 
lymphoïdes secondaires par des cellules présentatrices d’antigène professionnelles, telles 
que les cellules dendritiques, où il est présenté aux lymphocytes T et B qui circulent 
continuellement entre le sang et les tissus lymphoïdes secondaires. L’interaction entre 
une cellule présentatrice de l’antigène et les lymphocytes T et B spécifiques activent le 
lymphocyte B qui commencent à proliférer. Après quelques jours de prolifération, une 
   7
partie des cellules se différencie en plasmocytes, qui produisent des anticorps à faible 
affinité, essentiellement du type IgM. D’autres lymphocytes B migrent à l’intérieur de 
l’organe lymphoïde dans des follicules primaires. Elles continuent de proliférer en 
formant, avec l’aide de lymphocytes T et en présence de l’antigène, un centre germinatif. 
C’est dans ces centres germinatifs que surviennent le changement de l’isotype des 
anticorps produits par un lymphocyte B, ainsi que les mutations somatiques et la sélection 
des clones B produisant les anticorps ayant des plus hautes affinités pour l’antigène. C’est 
ce processus, initié dans les centres germinatifs, qui est appelé maturation de 
l’affinité/avidité. Les cellules B qui émergent de ce processus se développent soit en 
plasmocytes qui migreront dans la moelle osseuse pour y sécréter des anticorps de haute 
affinité, soit en cellules B mémoire, qui permettront une réponse immunitaire plus rapide 
et puissante en cas de réexposition au(x) même(s) antigène(s). 
Affinité et avidité des anticorps 
Une réponse immunitaire humorale contre un certain antigène peut être 
caractérisée en termes quantitatifs ainsi que qualitatifs. Le paramètre quantitatif le plus 
fréquemment déterminé est le taux plasmatique d’anticorps spécifiques pour un certain 
antigène/pathogène. Du côté qualitatif, l’on peut examiner l’isotype, l’affinité, l’avidité, 
la séquence génétique ainsi que l’activité biologique des anticorps. Ces paramètres sont 
en partie interdépendants. Par définition, l’affinité d’un anticorps pour un antigène est la 
force de liaison entre un seul site de liaison de l’anticorps et l’antigène dans une forme 
monovalente. Expérimentalement elle peut être mesurée par équilibre de dialyse et 
quantifiée par la constante d’équilibre de la loi d’action de la masse. L’avidité, aussi 
appelée “affinité fonctionelle”, est une mesure de la force de liaison entre l’anticorps 
entier et l’antigène dans sa forme naturelle, qui peut aussi être multivalente et/ou non-
soluble. Elle décrit donc plutôt une situation physiologique que théorique ou 
expérimentale et peut se distinguer clairement de l’affinité, surtout dans le cas d’anticorps 
IgM avec de multiples sites de liaison et pour un antigène multivalent. Elle se mesure 
avec un antigène en phase solide, par exemple par test d’élution, un ELISA (Enzyme 
Linked Immunosorbent Assay) modifié, dans lequel un réactif chaotropique comme 
l’isothiocyanate (NH4SCN) est utilisé pour dissocier les complexes antigènes-anticorps. 
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Puisque les anticorps de faible avidité sont élués par des concentrations plus basses de 
NH4SCN, la concentration utilisée pour éluer 50% des anticorps liés, appelée « index 
d’avidité » (AI), est une bonne mesure de l’avidité moyenne des anticorps analysés. Par 
ailleurs, cette méthode permet des analyses plus élaborées de sous-populations 
d’anticorps avec des avidités différentes. Une autre technique pour déterminer l’avidité, 
l’analyse des interactions biomoléculaires (BIA) par résonance plasmonique de surface, 
est plus performante dans le sens qu’elle permet aussi l’analyse de paramètres kinétiques 
de la liaison, mais elle ne se prête pas (encore) à l’examen d’une grande série de 
spécimens, comme il serait nécessaire pour implémenter des tests d’avidité en pratique 
clinique. 
Détermination de l’avidité des anticorps  en clinique 
La détermination de l’avidité d’anticorps pourrait devenir un outil clinique 
d’importance augmentante dans la caractérisation de réponses immunitaires à des 
vaccinations ou à des infections. Le concept de l’avidité comme mesure de qualité 
fonctionnelle des anticorps à été démontré dans plusieurs essais biologiques mettant en 
évidence une corrélation positive entre l’avidité et la capacité protectrice des anticorps 
spécifiques pour plusieurs germes (par exemple Haemophilus influenzae b, Streptococcus 
pneumoniae). Une étude cas-témoin à montré une avidité plus faible des anticorps chez 
des enfants infectés par Haemophilus influenzae b malgré une vaccination antérieure, par 
rapport à des enfants non infectés. Par ailleurs, la détermination de l’avidité des anticorps 
a prouvé son utilité dans la distinction entre une infection aiguë et une infection passée 
(ou non-primaire) par rubéole, toxoplasme, cytomégalovirus ou virus Epstein-Barr, ce qui 
peut être d’une importance primordiale dans le contexte d’une grossesse ou d’une 
immunosuppression. Dans la caractérisation des réponses vaccinales, la mesure de 
l’avidité semble être aussi utile, soit dans la comparaison de différentes nouvelles 
formules vaccinales (différentes avidités ont été mises en évidence dans des réponses à 
différents vaccins contre Streptococcus pneumoniae et Haemophilus influenzae), soit 
pour évaluer le succès de l’induction de la mémoire immunologique, ce qui peut être 
spécialement important chez des patients à risque infectieux élevé, comme par exemple 
après une transplantation médullaire. D’autres applications possibles de la détermination 
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de l’avidité des anticorps pourraient émerger dans le futur, comme par exemple dans la 
caractérisation de déficiences immunitaires. Une étude récente a par exemple incriminé 
une déficience dans la maturation de l’avidité dans un sous-groupe de patients souffrant 
d’immunodéficience commune variable (CIVD). 
Maturation de l’avidité chez l’enfant 
Dans l’enfance, il y a une maturation de la réponse humorale dans le sens 
quantitatif ainsi que qualitatif. Les taux d’anticorps de type IgG générés par des 
vaccinations contre des antgènes T-dépendants sont beaucoup plus bas chez des nouveau-
nés par rapport aux enfants plus âgés et aux adultes. Par exemple, même les vaccins les 
plus immunogéniques chez les nourrissons, tels que Haemophilus influenzae b ou tétanos 
toxoïde, ne parviennent pas à induire des réponses anticorps significatives chez les 
nouveaux-nés, des réponses progressivement plus importantes en terme de taux 
d’anticorps étant générées lorsque les enfants sont vaccinés à l’âge de 2-3, 4-6, ou 8-10 
mois. Peu de données sont encore disponibles concernant la différence de qualité des 
anticorps induits chez des jeunes enfants et des adultes. Alors que le mécanisme de 
l’hypermutation somatique semble fonctionnel déjà à la naissance, la maturité de la 
réponse d’anticorps, en tant que fréquence des mutations et sélection des lymphocytes B 
produisant les anticorps les plus avides, ne semble atteinte qu’après plusieurs mois, voire 
plusieurs années. Quelques études ont examiné les réponses à des vaccins 
polysaccharidiques conjugées, démontrant une maturation d’avidité durant les quelques 
mois suivant une vaccination. Par contre, à notre connaissance, il n’a jamais été 
investigué de manière approfondie si cette augmentation progressive de la fréquence des 
mutations somatiques au cours de l’enfance se traduit directement en une avidité 
croissante des anticorps induits par un antigène protéique, ni la durée nécessaire à cette 
maturation d’avidité.  
 
L’objectif de ce travail a donc été de développer un test d’élution permettant 
de mesurer l’avidité des anticorps IgG1 contre un antigène vaccinal utilisé de 
manière fréquente, à savoir le tétanos toxoïde (TT), dans des échantillons de sérum 
disponibles en petits volumes (microméthode), permettant l’évaluation de facteurs 
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influençant la maturation de l’avidité des anticorps chez des sujets sains ou malades. 
Après l’optimisation du test, il a été utilisé pour déterminer les valeurs de l’avidité 
des anticorps anti-TT dans des serums de 90 enfants en bonne santé apparente, âgés 
entre 5 mois et 15 ans. 
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1 Introduction 
1.1 Humoral immune response  
The immune system (Roitt 1998, Goldsby 2000, Janeway 2001) defends the host 
against infection by pathogens (i.e. bacteria, viruses, fungi, parasites). The first line of 
defense is provided by innate immunity, which prevents most infections or clears them at 
an early stage, usually within hours or a few days. Innate immunity generally functions 
by means of anatomical barriers or by molecular and cellular responses via receptors 
which recognize features common to many pathogens. Examples for such mechanisms 
are epithelial surfaces, interferons, the complement system, tissue macrophages, 
neutrophils, and natural killer cells. However, given the broad variability of pathogen 
structures and invading or replicating mechanisms, innate immune mechanisms are not 
always capable of clearing infectious foci, and this is where the adaptive immune 
response comes in as a second line of defense. The characteristic feature of the adaptive 
immune response is specificity of its effector mechanisms, which is a consequence of 
somatic hypermutation of genes encoding for receptor and effector molecules. Somatic 
hypermutation, a highly controlled mechanism, which may be activated in selected cells 
during the whole life of the host, permits generation of a much larger degree of diversity 
of immune response mechanisms than would be predicted from the size of the genome. 
This contributes to an optimal degree of adaptation of the immune response to a 
particular pathogen. 
The adaptive immune response consists of two lines, the cellular response, 
mediated through cytotoxic T-cells and type 1 helper T(Th1)-cells, which is directed 
mainly against intracellular pathogens, and the humoral response, mediated through B-
cells, often with the help of type 2 helper T(Th2)-cells, directed mainly against 
extracellular pathogens.  The principal effector molecules of the humoral response are 
antibodies (also called immunoglobulins), which help other effectors of the immune 
system to clear the pathogen by specifically binding to its surface. 
1.1.1 The antibody – effector function, molecular structure, germline organisation 
of the immunoglobulin loci 
Antibodies exist in two forms: B-cell membrane associated antibodies (i.e. B-cell 
receptors) are important in the activation of a B-cell to produce antibodies and to increase 
their avidity. Soluble antibodies on the other hand essentially have two known functions: 
Neutralization of the pathogen (e.g. by blocking a pathogen-host cell interaction 
necessary for infection of the latter) respectively of its product (e.g. a toxin), and 
opsonisation (i.e. coating of the pathogen, which facilitates ingestion and subsequent 
destruction of the pathogen by phagocytes, and further opsonisation or direct destruction 
in addition to perpetuation of the inflammatory response by the complement system). 
Antibodies are roughly Y-shaped glycoprotein molecules consisting of about 
equal-sized portions connected by a flexible hinge. The two extremities of the arms of the 
Y are called V (variable) regions. Their function is antigen binding, and they differ 
considerably between different antibody populations. The proximal parts of the Y arms as 
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well as its trunk are called the C (constant) region. It is much less variable, and its 
function is to activate effector cells and molecules. Antibodies consist of four covalently 
linked polypeptide chains: Two identical H (heavy) chains, whose amino-terminal parts 
consisting of 100 – 110 amino acids belong to the V regions and whose carboxy-terminal 
parts of approximately 330 or 440 (depending on the isotype [see below]) amino acids 
make part of the C region, and two identical L (light) chains consisting each of an amino-
terminal of 100 – 110 amino acids belonging to the V region and of a carboxy-terminal of 
approximately the same length belonging to the C region. There are several types of C 
regions determining the isotype (or class) of the antibody (IgG [with subclasses IgG1, 
IgG2, IgG3, and IgG4], IgA [IgA1, IgA2], IgM, IgD, IgE). The isotype produced by a B-
cell depends among other things on the stage of the immune response and the nature of 
the antigen. For example, early in the immune response after a first encounter with a 
pathogen, IgM are frequently produced, whereas later on there may be a switch (i.e. 
isotype switch) to other isotypes, e.g. to IgG subclasses. Different isotypes display 
different effector functions (e.g. complement is only activated by IgM and selected IgG 
isotypes), and whereas IgG, IgD and IgE exist in momomeric form, IgA are often 
covalently coupled to a dimer, and IgM to a pentamer. 
There are 3 different gene segments coding for 3 parts of a heavy chain’s V 
region: the V (variable) segment, the D (diversity) segment, and the J (joining) segment. 
The C segment codes for the C region. The heavy chain locus on the human chromosome 
14 consists of approximately 65 different functioning V gene segments, 27 D segments, 
and 6 J segments. Moreover it carries one C segment for each possible isotype. Light 
chain loci are on chromosomes 2 and 22. For light chain V regions, corresponding 
functional segment numbers are slightly smaller and there are no D segments at all. 
Otherwise the principle is the same.  
1.1.2 Humoral immune response to thymus(T)-dependent antigens – overview 
1.1.2.1 Antigen presentation and priming of helper T-cells 
At the site of infection, the antigen is captured by professional antigen presenting 
cells. In the periphery of the body, these are mostly dendritic cells, whereas in lymphoid 
tissues for example they may also be macrophages or B-cells. The antigen presenting 
cells then migrate from the site of infection to lymphoid tissues (e.g. lymph nodes, 
spleen, Peyer’s patches, tonsils). Antigen is processed and presented by major 
histocompatibility complex (MHC) class 2 molecules to naïve helper T-cells, whose T-
cell receptors specifically recognize the antigen:MHC complex. Other, co-stimulatory 
signals are necessary as well. This priming of T-cells takes place in the T-cell zones of 
lymph nodes and other secondary lymphoid tissues, and the T-cell becomes an armed 
helper T-cell. Whereas non-activated naïve T-cells continuously circulate between blood 
circulation and lymphoid tissues, armed helper T-cells are trapped in the T-cell zone of 
lymphoid tissues.  
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1.1.2.2 Activation of B-cells and formation of primary foci 
B-cells circulate between blood and lymphoid tissues as do T-cells. A B-cell 
enters a lymph node through specialized high endothelial venules. It then normally moves 
through the T-cell zone into the B-cell zone (i.e. the primary follicle). However, a B-cell 
carrying a receptor specific for an antigen, which is present in the lymphoid tissue and to 
which specific primed T-cells are trapped, is trapped as well in the T-cell zone. Through 
an interaction between the B-cell and a T-cell, the B-cell gets activated and undergoes 
several rounds of proliferation. Thereby, the primary focus of clonal expansion is 
established. The interaction between the cells happens as follows: The B-cell takes up 
antigen with its B-cell receptors (i.e. the membrane-bound immunoglobulins). Antigen is 
processed and presented on the cell surface on MHC class 2 molecules. A T-cell specific 
for a such presented antigen recognizes the MHC:antigen complex with its T-cell 
receptor. Moreover, a second signal is generated by contact of the CD40 molecule on the 
B-cell with the CD40 ligand (CD40L) on the T-cell. The activated armed helper T-cell 
now secretes IL-4 and other cytokines in order to further stimulate the B-cell. 
1.1.2.3 Formation of germinal centers 
After several days of proliferation in the primary focus, a B-cell can have 
different fates. Part of the cells undergo apoptosis, others become plasma cells secreting 
low-affinity IgM antibodies, and some cells migrate into a primary lymphoid follicle to 
continue proliferation and to form a germinal center together with a smaller amount of 
antigen-specific T-cells (Berek 1992, Berek 1999). The germinal center establishes a 
more efficient later response, designed to control longer lasting infections or re-
infections. Affinity maturation (i.e. somatic hypermutation and selection) and isotype 
switching happen at that moment. B-cells undergo several cycles of proliferation and 
positive selection. Non-selected B-cells die through apoptosis. In order to maintain the 
germinal center reaction, T-cell help as well as the presence of antigen are believed to be 
necessary. Antigen is stored in immune complexes on the surface of follicular dendritic 
cells. It is also possible that a certain antigen level is maintained by proliferation of 
pathogens within lymphoid tissue. It is thought that B-cells compete for antigen, which 
eventually remains available for highest affinity cells only. Whereas a germinal center 
has been initially built by numerous B-cells of several specificities, eventually only a few 
B-cell clones with the highest avidities survive. B-cells produced and selected during the 
germinal center reaction will either become high-affinity antibody secreting plasma cells 
and migrate to the bone marrow, or they may develop into memory B-cells (Meffre 
2001), which do not primarily produce antibodies, but which keep the changes they had 
undergone during the germinal center reaction in order to make a more efficient 
secondary immune response possible. The molecular mechanisms of germinal center 
formation are not completely elucidated. Cytokines such as tumor necrosis factor alpha, 
lymphotoxins as well as their receptors seem to be indispensable (Berek 1999).  
1.1.3 Generation of antibody diversity – the germinal center reaction 
Antibody diversity is generated by the following mechanisms: 1) Combinatorial 
diversity (i.e. coupling together of different V, D, and J segments; coupling together of 
different heavy and light chains; isotype switching), 2) junctional diversity (i.e. 
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“imprecise” joining of the different segments, so that nucleic acids may randomly be 
deleted or added), and 3) somatic hypermutation (see below). Joining together of the V 
region segments, as well as junctional diversity and somatic hypermutation happen at 
DNA level and are called somatic recombination. Isotype switching happens at RNA 
level through alternative splicing. 
In B-cells, somatic hypermutation leads to diversification of the V region genes 
(Weigert 1970, Bernard 1978). This mechanism introduces point mutations at a high rate 
(i.e. 1/1000 base pairs per cell division cycle) into the rearranged genes coding for V 
regions of heavy and light immunoglobulin chains, so that approximately on every 
division one nucleotide change is introduced (Nossal 1992).  On the amino acid sequence 
level, such mutations may be silent (i.e. no change), neutral (the change does not alter the 
function of the antibody), negative (the antibody becomes non-functional or binding 
strength is diminished), or positive (binding strength is increased). During an immune 
response to an antigen, B-cells with positive changes will be selected and further 
stimulated to enter a new proliferation and hypermutation/selection cycle, or to leave the 
germinal center in order to become an antibody secreting plasma cell or a memory B-cell, 
whereas other B-cells will undergo apoptosis. Thus, affinity maturation would not be 
possible without a strict selection mechanism, as otherwise production of B-cells would 
be too big. For instance, the importance of apoptosis in affinity maturation was assessed 
by transgenic induction of overexpression of the apoptosis inhibitor Bcl-xL in B-cells. 
The subsequent antibody response to a specific hapten showed persistence of clones 
carrying immunoglobulin gene sequences which were absent in control mice, and the 
average affinity of serum antibodies was lowered (Takahashi 1999). However, affinity 
maturation does not continue endlessly. There seems to be a so-called “affinity-ceiling” 
above which a B-cell would not have any selection advantage anymore, as other 
parameters, such as diffusion coefficients and time used for signal transduction and 
endocytosis, would become limiting factors of antibody efficacy (Foote 1995). On a 
molecular level, such point mutations most often lie within the V region. In proliferating 
B-cells, non-silent point mutations are mostly clustered within three hypervariable 
regions called CDR1 to 3 (complementarity determining regions) (Griffiths 1984, 
Kaartinen 1983, Kabat 1991), whereas silent mutations are evenly distributed within the 
whole V region. Thus, selection seems to favor mutations in the CDRs, which might be 
explained by the fact that the three CDRs together constitute the antigen-binding surface 
of the immunoglobulin V region. However, analysis of murine antibody:antigen 
complexes showed that in spite of a concentration of the majority of hypermutations to 
CDRs, somatic replacements occurred mainly in residues which were not in direct contact 
with the antigen (Ramirez-Benitez 2001). Whereas replacement of contacting residues 
seems to have an adverse effect on binding strength, mutations of more distant residues 
may have a positive impact. The precise mechanism of somatic hypermutation has not 
been completely elucidated yet. It seems independent of the actual V region sequence 
(Azuma 1993) and apparently takes place only under stringent conditions of B-cell 
activation by antigen and interaction with helper T-cells and follicular dendritic cells (see 
below). It has recently been described to affect a non-immunoglobulin gene sequence as 
well, i.e. an intron of the BCL-6 gene sequence (Pasqualucci 1998). 
Whereas the B-cell undergoes gene segment rearrangements in central lymphoid 
tissue (i.e. bone marrow) before antibody production, somatic hypermutation as well as 
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isotype switching occur for the first time during the second phase of the primary immune 
response in germinal centers of the secondary lymphoid organs (e.g. lymph nodes). 
However, affinity maturation can continue through secondary and later immune 
responses (Berek 1999).  
1.2 Assessment of the humoral immune response 
An antibody response to infection or vaccination can be characterized in terms of 
quantity as well as quality. Quantitative measures are serum antibody levels and 
frequencies of B-cells specific for a certain antigen. Determination of presence and levels 
of specific antibodies in serum, often done by enzyme linked immunosorbent assay 
(ELISA), can give answers to clinical questions, such as presence or absence of infection, 
stage of infection, or presence or absence of protective antibody levels against a pathogen 
or a toxin. However, not only quantity but also quality of circulating antibodies may be of 
importance for the efficacy of prevention or clearing of infection. Qualitative parameters 
characterizing an antibody response are antibody isotype, affinity, avidity, 
immunoglobulin gene sequence, and biological activity. These parameters are 
interrelated, i.e. they may be correlated (discussed below).  
1.2.1 Antibody affinity 
Antibody affinity is defined as the strength of binding between a single antigen 
binding site of the antibody and a monovalent antigen (Eisen 1964, Siskind 1965, Siskind 
1969, Steward 1983, Goldblatt 1997). The antibody/antigen interaction in a homogenous 
solution in equilibrium can be described with the law of mass action equation: Ka = ka/kd 
= 1/Kd= [Ab:Ag]/[Ab][Ag]), where Ka is the association equilibrium constant, Kd the 
dissociation equilibrium constant, ka the association rate constant, kd the dissociation rate 
constant, [Ab] the concentration of free antibody, [Ag] the concentration of free antigen, 
and [Ab:Ag] the concentration of bound antibody:antigen complexes. Affinity is typically 
expressed by either the association or the dissociation equilibrium constant. A high 
association respectively a low dissociation equilibrium constant indicate a high affinity. 
Experimentally, antibody affinity is determined by equilibrium dialysis: A 
dialysis chamber is separated into two parts by a semipermeable membrane, which is 
only permeable for the antigen. A known amount of antibody is placed into one part of 
the chamber, and a known amount of antigen into the other part. Antigen then diffuses 
across the membrane, and at equilibrium, free antigen concentration is measured. The 
quantity of bound antigen can then be calculated, and Kd can then be determined 
mathematically or graphically by performing a Scatchard analysis. For solutions 
containing a mixture of antibodies with different affinities, an average equilibrium 
constant can be determined. Another method to determine antibody affinity is 
fluorescence quenching, where antibody binding aborts fluorescence of previously 
labelled antigen. Antibody concentration needed to reduce fluorescence to a certain 
degree can therefore be taken as a measure of affinity. 
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1.2.2 Antibody avidity 
The affinity constant describes the strength of interaction between single antigen 
binding sites with independent binding behavior on one hand and soluble monovalent 
antigens (haptens) on the other hand in solutions containing pure preparations of the two 
components. However, this corresponds rather to experimental conditions than to 
physiological settings. In reality antibodies are multivalent, containing between 2 (IgG) 
and 10 (IgM) antigen binding sites, and antigens as well are often multivalent and/or 
nonsoluble. For thermodynamic reasons, total binding strength is strongly influenced by 
the number of binding sites, and moreover, binding at one site may induce 
conformational changes in the antibody and/or the antigen, thus influencing binding at the 
other site(s) (Goldblatt 1997). Therefore the concept of avidity, or functional affinity, has 
been introduced (Karush 1970, Karush 1976). Antibody avidity is defined as the overall 
binding strength of an antibody to an antigen. (However, in literature, the term affinity is 
sometimes used as well to describe avidity.) 
Avidity is measured by two categories of solid phase assays: a) competitive 
inhibition assays, and b) elution assays (Pullen 1986, Goldblatt 1997). In both of them the 
antigen is attached to a solid support. In the competitive inhibition assay, antibody is 
added in solution at a fixed concentration, together with free antigen in different 
concentrations, and the amount of antigen which inhibits solid phase binding by 50% is 
determined. The less antigen needed, the stronger the avidity. In elution assays, the 
antibody is added in solution. After obtaining a state of equilibrium, a chaotrope or 
denaturant agent (e.g. isothiocyanate, urea, or diethylamine) is added in different 
concentrations to disrupt antibody/antigen interactions. The amount of antibody resisting 
elution is determined thereafter with an ELISA. The higher the avidity, the more 
chaotropic agent is needed to elute a certain amount of antibody. The relative avidity of a 
heterogeneous mixture of antibodies can be expressed as the avidity index (AI), equal to 
the concentration of eluting agent needed to elute 50% of the bound antibody. Refined 
analysis of data can be performed by determining percentages of eluted antibody at 
different concentrations of the eluting agent. Whereas avidity assays probably describe 
the reality of antibody/antigen binding better than affinity assays, they still represent an 
artificial system. The AI is not an absolute but only a relative measure, and for identical 
pairs of antibody/antigen, it strongly varies as a function of the precise conditions of the 
assay. Moreover, the coating antigen may be different from antigen found in 
physiological conditions, i.e. with respect to density and conformation (Goldblatt 1997). 
Information on low-avidity antibodies might be lost, as on reaching the equilibrium 
before addition of the eluting agent, lower proportions of low-avidity antibody are bound 
to the coating antigen than of higher-avidity antibody, which means that higher-avidity 
antibodies are preferentially detected and analyzed (Butler 2000). 
A more recent technology to assess antibody/antigen interaction is binding 
interaction analysis (BIA) based on surface plasmon technique (Malmqvist 1993). Aside 
from measuring binding strength, it permits real time determination of binding kinetics, 
such as association and dissociation rate constants. A further advantage of this highly 
sensitive method is that labelling of any of the interactants is not necessary. A sensor 
chip, consisting of a glass slide coated with a thin metal film, to which a surface matrix is 
covalently attached, is coated with one of the interactants, for example with antigen. A 
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solution containing the other interactant (e.g. the antibody) is allowed to flow over its 
surface. A continuous light beam is directed against the other side of the surface, and its 
reflection angle is measured. On binding of antibody to the antigen, the resonance angle 
of the light beam changes (as it depends on the refractive index of the medium close to 
the reactive side of the sensor, which in turn is directly correlated to the concentration of 
dissolved material in the medium). It is subsequently analyzed with the aid of a computer. 
Unfortunately, this sophisticated approach would not allow determination of a large 
number of small volume samples.  
1.2.3 Immunoglobulin gene sequence 
Immunoglobulin genes of antigen specific B-cells can be analyzed by 
amplification of nucleic acids by polymerase chain reaction (PCR) and subsequent 
determination of the gene sequence (Weigert 1970). This permits detection and 
characterisation of subtle molecular differences between antibody populations which may 
not always be detected on affinity testing. However, it provides no indication on the 
influence, either positive or negative, of mutations on antibody affinity. 
1.2.4 Biological activity of antibody 
Biological activity of antibodies can be assessed by various protocols. For 
instance, complement-mediated bactericidal antibody activity can be measured in vitro by 
incubating bacteria together with antibody and complement factors. Subsequent culturing 
of the remaining bacteria permits to measure the quantity of antibody needed to kill 50% 
of the bacteria (Weinberg 1986). Similarly, virus neutralisation capacity of antibodies can 
be assessed by incubating virus particles with neutralizing antibodies followed by transfer 
onto host cell monolayers. After a further incubation step, numbers of infected cells can 
be estimated by counting plaques or by detecting viral antigen expressed on host cells 
(Kalinke 2000). Both approaches are of course limited to pathogens which can be grown 
in vitro. Methods to assess in vivo activity of antibodies include administration of 
pathogen-specific immunoglobulins to animals with are subsequently infected with the 
corresponding pathogen. Titration of the minimal antibody dose to prevent a certain 
endpoint (e.g. death, presence of pathogen above a certain level in selected tissues, etc.) 
generates a value of biological significance (Bachmann 1997, Usinger 1999). 
1.2.5 Relationships between different qualitative parameters of antibody responses 
Affinity and avidity results are not always correlated. For example, early in a 
primary immune response the predominant antibody isotype is IgM. These antibodies can 
be produced and secreted before somatic hypermutation of selected clones has taken 
place, which helps to gain time at the expense of affinity. However, as IgM molecules 
contain 10 antigen binding sites, the binding to a multivalent antigen increases 
thermodynamic stability of the complex and thus avidity (Steward 1983). In other cases 
however, a positive correlation can be found, affinity ranking of murine monoclonal 
antibodies to dinitrophenyl coupled to bovine serum albumine by equilibrium dialysis 
gave almost the same results as an ammonium thiocyanate elution assay  (Macdonald 
1988). 
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There are many examples for a correlation between affinity and somatic mutations 
of immunoglobulin variable regions. For example, mice were immunized with the carrier 
protein coupled hapten 2-phenyloxazolone and the immune response was analyzed. 
Whereas almost no mutations could be found one week after immunisation, many 
mutations could be detected another week later which were significantly more frequent in 
the complementarity determining regions. In parallel affinity increased about 10 times 
(Griffiths 1984). 
Examples for a correlation between antibody avidity and protective capacity 
assessed in biological assays clearly exist as well. In infants immunized with 
Haemophilus influenzae type b conjugate vaccines, complement-mediated bactericidal 
serum activity was shown to be correlated with antibody avidity (Schlesinger 1992). 
Avidity of antibodies to Pneumococcal polysaccharides in adults was found to be 
correlated with opsonaphagocytic activity and with mouse-protective activity (Usinger 
1999). Another group found a tendency to a negative correlation between concentration 
of Pneumococcal polysaccharide specific antibodies needed for killing of bacteria and 
avidity in infants (Anttila 1999a). Direct assessment of the significance of antibody 
avidity for protection against infection in humans is difficult to conduct, however there is 
evidence for a positive role of avidity. A small case-control study for example found IgG2 
avidity decreased in children who had experienced Haemophilus influenzae type b 
vaccine failure (Breukels 2002).  
However, there is also data which supports somewhat less the concepts of 
antibody avidity maturation and of a positive correlation between avidity and protective 
capacity in an immune response. Mice were repeatedly inoculated with vesicular 
stomatitis virus (VSV), a cytopathic virus closely related to rabies virus, which is cleared 
by a neutralizing antibody response. Antibodies produced after a primary infection at 6 
days after inoculation, after secondary infection at 12 days, or after hyperimmunisation at 
150 days were found to be of high avidity without any evidence of affinity maturation 
(Roost 1995). When some of these antibodies were tested in vitro and in vivo in severe 
combined immunodeficient (SCID) mice, there was a strong positive correlation between 
avidity and in vitro neutralizing capacity. However, above a minimal avidity threshold, 
no correlation could be found between in vivo minimal protective serum concentration 
and avidity or in vivo neutralizing capacity (Bachmann 1997). The same group then 
tested recombinant single-chain antibody fragments, consisting basically of a single V 
region, of one antibody found during the secondary response and detected to be devoid of 
hypermutations, as well as single-chain antibody fragments which additionally 
incorporated one or more frequently found hypermutations. They found one 
hypermutated antibody fragment of 300-fold increased affinity compared to the germ-line 
precursor. However, when these single-chain fragments were crosslinked with 
immunoglobulins, imitating polyvalent binding of an antibody molecule, the avidity of 
the germ-line precursor strongly increased, whereas the binding capacities of the 
hypermutated fragments did not further improve, which reduced the binding difference to 
a factor of 10 to 15, instead of 300. Moreover, the several non-hypermutated antibodies 
showed in vivo protective capacities in concentrations which can be expected during an 
early immune response (Kalinke 2000). Thus, even if it cannot fully be excluded that 
avidity maturation might have been missed when investigating only after day 6 (Foote 
1995), the authors speculate that the phenomenon of affinity maturation may be of less 
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importance in pathogens cleared by early neutralizing antibodies than in the artificial 
situation of haptens, where most of the affinity maturation studies have been conducted. 
These contradictory observations highlight the influence of both the nature of the antigen 
and the methods used for evaluation, a priori rendering difficult generalization of 
experimental observations. 
1.3 Maturation of the humoral immune response in early life 
The level of IgG antibody responses to T-dependent antigens that can be 
generated in human infants is much lower than that achieved in older children and adults. 
For example, even the most immunogenic infant vaccines, such as Haemophilus 
influenzae type b or tetanus toxoid vaccines, fail to induce significant antibody responses 
in >90% neonates (Kurikka 1995, Lieberman 1995), whereas progressively higher serum 
antibody concentrations are elicited when immunization is given at 2-3, 4-6, or 8-10 
months of age (Einhorn 1986, Rowe 2000) Such age-dependent limitations of primary 
antibody responses are observed with most vaccines (reviewed in Siegrist 2001).  
Whereas the quantitative difference in antibody response between infants and 
adults is well substantiated (serum levels of IgG antibodies, persistence of serum 
antibodies), there may also be qualitative differences. Qualitative difference between 
early age and adult antibody responses may concern antibody avidity, but limited data 
exists on kinetics of avidity maturation to vaccines or infections in infants and children. 
The relative capacity to induce high-avidity antibodies following immunization in early 
life has long been questioned. In rodent models, previous analyses have shown that 
antibody responses to haptens (trinitrophenyl, dinitrophenyl), elicited with corresponding 
protein conjugates, are characterized by low-affinity antibody-secreting cells following 
immunization in the first 2 weeks of life (Goidl 1974, Marshall-Clarke 1975, Marshall-
Clarke 1978, Doria 1978, Sherr 1979). In humans, it is clear that the mechanisms 
implicated in avidity maturation, i.e. somatic mutation of immunoglobulin genes and 
selection of mutated B-cell clones, function already from birth onwards, be it at a 
quantitatively and maybe qualitatively reduced level. Somatic hypermutation of 
immunoglobulin genes is present but minimal in cord blood B-cells (Cai 1992, van Es 
1992, Nicholson 1995) and present at significant levels at 4 years of age (Klein 1994). 
Studies performed in infants indicated a progressive increase of somatic mutation of 
immunoglobulin genes between 2 and 10 months of age, with evidence for selection 
found from 6 months onwards only (Ridings 1997, Ridings 1998). Avidity maturation 
was shown to occur following early infant immunization with conjugated polysaccharide 
vaccines (Goldblatt 1998, Goldblatt 1999, Pichichero 1999, Richmond 2001, Joseph 
2001). However, it has been reported that following Neisseria meningitidis infection, 
infants produced specific antibodies of a significantly lower average avidity than older 
children, which correlated with the absence of bactericidal activity in infant sera (Pollard 
2000). Since early protection against infection essentially depends on the presence of pre-
existing neutralizing serum antibodies (Ahmed 1996), potential limitations in the capacity 
to induce high-avidity serum antibodies in early life is of significant concern for early life 
immunization strategies (Schallert 2002).  
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Thus, the somatic hypermutation machinery seems to be functional already from 
the time of birth onwards, but maturity in terms of mutation and selection frequency 
seems to be achieved after at least several months only. However, whether the increasing 
frequency of somatic mutations in immunoglobulin genes translates directly into 
increasing antibody avidity in children, has not been thoroughly examined for protein 
antigens to our knowledge. The only available data relates to conjugated polysaccharide 
vaccines, showing evidence of avidity maturation over a period of a few months to 1 year 
(Goldblatt 1998, Anttila 1998, Pichichero 1999).  
 
The objective of this work was thus to develop an ELISA-based elution assay 
which could be used to measure the avidity of IgG1 antibodies to a frequently used 
vaccine antigen (tetanus toxoid [TT]) in small volume samples, allowing subsequent 
evaluation of factors affecting avidity maturation in healthy or diseased individuals. 
Following optimisation, this avidity assay was used to determine the avidity values 
in sera of 90 immunized apparently healthy children between 5 months and 15 years 
of age.  
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2 Material, Methods and Patients 
2.1 Material 
Flat-bottomed 96 well microtiter plates (Nunc MaxiSorpTM) were purchased from 
Life Technologies, Basel, Switzerland), tetanus toxoid (TT) was obtained from Aventis 
Pasteur (Lyon, France), Tetuman was from Berna (Bern, Switzerland), biotin-conjugated 
goat anti-human-IgG antibodies, as well as horse radish peroxidase(HRP)-conjugated 
extravidine, and 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) were 
obtained form Sigma (St. Louis, MO, USA), HRP-conjugated monoclonal mouse anti-
human-IgG1 antibodies were from Zymed (San Francisco, CA, USA), ammonium 
isothiocyanate (NH4SCN) was purchased from Fluka (Buchs SG, Switzerland). All the 
remaining chemical substances were reagent grade and purchased from Merck 
(Darmstadt, Germany). The automatic plate washer SkanWash400, the Microplate reader 
(vmax kinetic) and software (SOFTmax®PRO) were obtained from Molecular Devices 
Corporation (Sunnyvale, CA, USA).   
2.2 Methods 
2.2.1 Determination of serum levels of TT-specific IgG antibodies 
Serum levels of TT-specific IgG antibodies were determined by ELISA as 
follows: Microtiter plates were coated with 50 µL/well of TT diluted in carbonate buffer 
(50 mM, pH 9.6) at a concentration of 5 ug/mL, by incubation over night at 4°C. After 3 
washings with 0.9% NaCl containing 0.05% Tween20 using the SkanWash400, the plates 
were saturated with 100 µL/well of 1% gelatine diluted in phosphate buffered saline 
(PBS). After blotting the plates on absorbent paper, 50 µL/well of serum samples were 
added in eight serial dilutions in dilution buffer (PBS containing 0.2% gelatine and 0.05% 
Tween20), beginning at a dilution of 1:50 and progressing by factor 2. After an 
incubation at room temperature on a shaker for 30 min and four subsequent  washings, 
biotin-conjugated goat anti-human-IgG antibodies diluted 1:1000 in dilution buffer were 
added at 50 µL/well. After 30 minutes of incubation at room temperature on a shaker and 
5 washings, HRP-conjugated extravidine diluted 1:1000 in dilution buffer were added at 
50 µL/well. After further 30 minutes of incubation at room temperature on a shaker and 5 
washings, 50 µL/well of freshly prepared substrate solution (0.1% ABTS, 30.5 mM citric 
acid monohydrate, 44 mM Na2HPO4⋅12H2O, and 0.01% H2O2) were added, and the plates 
were incubated for 20 minutes in the dark at room temperature. Absorbance was read at 
405 nm. 
In each plate, a serially diluted standard sample of known antibody concentration 
(Tetuman) was included, the results were interpolated on the standard by 4-parameter 
fitting with the SOFTmax®PRO software and expressed in mIU/mL. To test the 
reproducibility of the method, a positive as well as a negative control sample were 
included in each plate. 
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2.2.2 Determination of avidity of TT-specific IgG1 serum antibody 
In order to avoid potential biases resulting from the interference of antibodies of 
distinct isotypes, we performed our avidity analyses on the main isotype elicited by TT 
immunization, i.e. IgG1. An isothiocyanate elution assay based on the method described 
in the literature (Goldblatt 1997) was adapted in order to measure the avidity of TT-
specific IgG1 antibodies. Coating and saturating of the plate were done as described in 
3.2.1. Sera were diluted in dilution buffer, for each serum a dilution factor was chosen to 
give an optical density (OD) in the upper linear part of the standard curve (OD around 
1.5), with a minimal dilution of 1:50. The diluted serum samples (50 µL/well) were 
incubated for one hour at room temperature on a shaker. After four washings, 100 
µL/well of 0, 0.25, 0.5, 1, 2, 3, 4, or 5 M NH4SCN in dilution buffer were added and the 
plate was incubated for 15 minutes at room temperature on a shaker. After 4 washing 
steps by hand, HRP-conjugated monoclonal mouse anti-human-IgG1 antibodies diluted 
1:500 in dilution buffer were added at 50 µL/well. After an incubation of one hour at 
room temperature on a shaker and 5 washings, substrate solution was added and the 
absorbance was read as described in 3.2.1. 
Each serum was run in duplicate. In each plate, a serially diluted standard sample 
(Tetuman), to which an anti-TT IgG1 concentration was arbitrarily assigned, was included 
without addition of NH4SCN. The results were interpolated as in 3.2.1 and expressed as 
mAU/mL of antibody remaining bound to the antigen after the NH4SCN elution. To test 
the reproducibility of the NH4SCN-independent part (i.e. the ELISA part) of the method, 
a positive as well as a negative control sample were included in each plate. For 
assessment of the reproducibility of the NH4SCN-dependent part (i.e. the elution assay), a 
positive control sample of high avidity was added and run in duplicates. 
The avidity index (AI), corresponding to the concentration of NH4SCN required 
to elute 50% of the antibody, was calculated as follows: The ODs were transformed into 
antibody concentrations with the aid of the standard curve (see above). The percentage of 
eluted antibodies was calculated for each NH4SCN concentration. These percentages 
were log transformed, and the two nearest values around log10(50) were chosen. By linear 
interpolation, the NH4SCN-concentration corresponding to an antibody concentration of 
log10(50) was determined. The AI can be seen as a measure of average avidity of a 
population of  antibodies with possibly heterogeneous avidities. 
The elution profile was expressed as a histogram (Aviscan) giving the percentages 
of antibody eluted between two NH4SCN concentrations (respectively the percentage still 
adhering at the highest NH4SCN concentration) plotted against the corresponding 
concentrations. The Aviscan gives information about the distribution of different avidities 
within an antibody population of heterogeneous avidities. Arbitrarily, the antibody 
fraction eluted between 0 and 1 M of NH4SCN was designed as low avidity antibody 
fraction, whereas the fraction not eluted at 3 M was designed as high avidity antibody 
fraction. 
2.2.3 Statistical analysis 
To examine the relationship of AI (as well as of the percentages of low and of 
high  avidity) of TT-specific IgG1 antibodies with age as well as with serum levels of TT-
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specific IgG antibodies, linear regression using the method of least-squares fitting was 
performed. Briefly, this is a mathematical procedure for finding the best fitting curve to a 
given set of observed points by minimizing the offsets (i.e. errors) of the observed points 
from the theoretical model curve. Inter-observer variability of avidity assay results was 
tested for a series of AIs, which had been independently measured by two persons. The 
degree of correspondence between the two sets of values was described by an estimation 
of Pearson’s correlation coefficient, a measure of linear relationship between two 
variables. To test intra-observer variability, particularly whether day-to-day variation was 
greater than variation within one day, covariance parameter estimates were generated. 
These are measures of the overall deviation of single measured values from a value 
chosen to minimize offsets. Formal statistical testing was not done due to insufficient 
sample size. For the same reason, the effect of the degree of serum dilution on variability 
of the measured avidity could only be tested by simple descriptive summary statistics. All 
analyses were performed using SAS 8.0. 
2.3 Subjects and serum samples 
To determine the evolution in avidity of TT-specific IgG1 antibodies with age, 
serum samples of children of different ages were tested. Serum samples had been 
harvested for determination of TT-antibodies to rule out immunodeficiency or define the 
needs for subsequent vaccine doses. Most children had received 3 TT vaccine doses in 
the first year of life, followed by a booster in the 2nd year of life and at 4-6 years of age. 
Samples with TT-specific IgG serum levels less than 1000 mUI/mL, as well as from 
children with either unknown tetanus immunization history or a previously known or by 
time of blood testing newly discovered immunodeficiency (e.g. lymphoma, iatrogenic 
immunosuppression, treatment with intravenous immunoglobulins, etc.) were excluded 
from the analysis. After reception of the blood, serum had been separated by 
centrifugation and thereafter stored at –20 °C until analysis. No bleeding was performed 
for the study, and no other analysis than determination of the quantity and the avidity of 
TT-specific antibodies was performed. 
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3 Results 
3.1 Development and validation of the ammonium isothiocyanate elution assay 
3.1.1 Introduction 
To determine the avidity of TT-specific IgG1 serum antibody, a NH4SCN elution 
assay was adapted, based on the general protocol described in the literature (Goldblatt 
1997). This is a modified ELISA assay. Between incubation of the antigen-coated wells 
with antibody-containing serum and addition of the second antibody, it includes an 
additional step of elution of bound antibodies by the chaotropic agent NH4SCN. Antibody 
subpopulations of different avidities are assessed by means of differential elution at 
incremental concentrations of NH4SCN and thereafter measuring the corresponding 
degree of antibody release. Low avidity antibodies are eluted at lower NH4SCN 
concentrations, high avidity antibodies at higher NH4SCN concentrations. 
3.1.2 Resistance of the coating antigen TT to NH4SCN 
Testing of resistance of the coating antigen TT to NH4SCN was assessed by 
incubating the antigen after coating with NH4SCN for 15 minutes on a shaker at room 
temperature. The amount of antigen remaining on the plate was determined by measuring 
its binding capacity of a known amount of antibody. Up to a NH4SCN concentration of 3 
M, no significant antigen denaturation or elution were observed, whereas above 3 M a 
limited degree of denaturation or elution was detected (Figure 1). We therefore decided to 
evaluate elution properties only within an NH4SCN concentration interval of 0 – 3 M, as 
at higher concentrations, a reduction of antibody binding could in theory be attributed to 
antigen denaturation/elution as well as to antibody elution. It should be noted that 3M is 
already a high NH4SCN concentration, so that this was not a limitation to further 
development of the assay. 
3.1.3 Duration of NH4SCN incubation 
Varying duration of NH4SCN incubation showed a strong influence on the results. 
The longer the incubation, the lower was the AI (AI of control serum depending on 
NH4SCN incubation time: 4.0 M at 5 min, 3.8 M at 10 min, 3.5 M at 15 min, 3.4 M at 20 
min, 3.1 M at 40 min). We decided in favour of a duration of 15 minutes for all our 
experiments, as chosen by several authors for this type of assay (Pullen 1986, Goldblatt 
1997). This finding illustrates the relative nature of the AI, depending on the conditions 
of the assay, and therefore the need of standardisation and precise following of a 
protocol. 
3.1.4 Dilution of the serum sample 
Variation of serum sample dilution used to assess avidity seemed to have little 
effect on the results, provided that the measured optical density in the well without 
NH4SCN addition was situated in the linear part of the standard curve. In the two samples 
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tested at four different dilutions each, the AI proved to be very robust, whereas the 
percentages of high and especially of low avidity antibodies were more variable (Table 
1). This is in accordance with the variability of avidity control serum values described 
below, and therefore this variability seems to reflect inherent properties of the assay 
itself.  
3.1.5 Reproducibility 
To test the intra-observer variability of the AIs generated in the assay, a high 
avidity control serum was included to each plate. In total, 5 test series on different days of 
4 to 10 parallel test plates were run. As shown in Table 2, overall degree of 
reproducibility was very high for AI, high for percentage of high avidity antibodies, and 
lower for percentage of low avidity antibodies. Weighted average intra-day variability 
was comparable (data not shown). As expected, day-to-day variation of high avidity 
control serum AI was greater than within-day variation, as indicated by a covariance 
parameter estimate for day-to-day variation which was 16 times larger than that for 
within-day variation (0.002375 vs. 0.00015).  
Intra-observer variability was low. 59 different serum samples were tested by two 
persons each. Reproducibility was high with Pearson’s correlation coefficient estimated 
at rho = 0.95 (p<0.0001). This illustrates the robustness of the developed assay, allowing 
its use for evaluation of clinical samples. 
3.2 Avidity maturation of TT-specific antibodies in children 
3.2.1 Introduction 
The primary objective of this study was to  describe the avidity maturation of anti-
tetanus antibodies in immunized children.  This was done by assessing the relationship of 
avidity parameters (i.e. AI, percentages of low and high avidity fractions of TT-specific 
IgG1 antibodies) with age. The secondary objective was to examine the relationship 
between avidity maturation and serum concentration of anti-tetanus antibodies in this 
population, i.e. to define whether children raising the highest antibody responses were 
those raising antibodies of highest avidity, and inversely. This was done by comparing 
avidity parameters of TT-specific IgG1 antibodies to the serum concentration of TT-
specific total IgG antibodies. For this purpose, avidity of IgG1 antibodies to TT as well as 
serum levels of IgG antibodies to TT were measured in serum samples of 90 apparently 
healthy children of different ages, as described in 3.3. 
3.2.2 Avidity and age 
3.2.2.1 Avidity index and age 
Figure 2 shows the measured AIs as well as the fitted curve, plotted against the 
age at serum sampling. Overall, the AI is increasing with age. The increase is most 
marked during the first five years, where the values also seem more heterogeneous than 
in older children. Later on, a plateau seems to be reached around 3 M. However, as the 
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values above 3 M were treated as equal to 3 M for reasons of antigen instability at higher 
NH4SCN concentrations, it is possible that the real plateau lies at a higher value. 
Therefore, the time point when the maturation process reaches completion is not 
accurately determined by this experiment. Nevertheless, maturation of AI is clearly 
ongoing until the fifth year of age, which is an unexpected observation. Statistical 
analysis confirms a significant positive correlation of the AI with age, which can be 
approximated by the function AI[M] = [2.3324 + 0.6989*log10(age[years])] (p<0.0001). 
The correlation is stronger between AI and log10(age) than between AI and age (not 
shown). 
3.2.2.2 High and low avidity fractions and age 
Figure 3 shows the measured high and Figure 4 the low avidity fractions 
(expressed as percentages of total antibody) together with their respective fitted curve, 
plotted against age. Whereas the percentage of high avidity antibodies rises from around 
30% of total TT-specific IgG1 to 55% towards the end of the maturation process, the 
percentage of low avidity antibodies decreases from around 20% to 10% with increasing 
age. Statistical analysis shows a significant positive correlation of the percentage of high 
avidity antibody with log10(age) (p<0.0001), approximated by the function (% high 
avidity antibodies) = 30.203 + 23.551*log10(age[years]). Percentage of low avidity 
antibody was found to be associated with exp(-age) (p<0.0001), described by the function 
(% low avidity antibodies) = 9.3503 + 33.876*exp(-age). Thus, the avidity maturation of 
TT IgG1 antibodies is characterized by a progressive increase of high avidity antibodies 
and decrease of low avidity antibodies. 
3.2.3 Avidity and serum levels 
Figure 5 shows the AIs of TT-specific IgG1 antibodies plotted against the serum 
levels of TT-specific total IgG antibodies. No statistically significant correlation was 
found between these two measured values in our sample of 90 patients (p=0.19). The 
same applies to the percentages of high (p=0.26) and of low (p=0.32) avidity antibodies 
in relation to IgG serum levels. Thus, we observed no correlation between the magnitude 
of TT antibody titers elicited in children and their avidity. 
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3.3 Figures 
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Figure 1. Antigen resistance to different NH4SCN concentrations. After coating with TT 
antigen and subsequent washing, the wells were incubated with NH4SCN  in various 
concentrations for 15 minutes at room temperature on a shaker. Thereafter, an ELISA 
measuring the binding of IgG1 of the standard serum sample to the antigen was done. 
Each sample was run in duplicate. Results are expressed in % of binding (compared to 
the samples with 0 M NH4SCN) as a function of NH4SCN concentration, and are shown 
for the serum sample dilution containing a TT-specific IgG1 concentration of 125 
mAU/mL. Results are similar for concentrations between 62.5 and 500 mAU/mL (data 
not shown). 
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Sample  Dilution AI
[M]
Low avidity 
antibody
(% of total) 
High avidity 
antibody 
(% of total) 
1  1:50 2.03 24.19 25.40 
  1:100 2.01 22.69 24.64 
  1:200 2.29 19.02 27.06 
  1:400 2.21 17.73 25.89 
    
 Mean  2.13 20.91 25.75 
 SD  0.14 3.04 1.02 
 CV  6.34 14.52 3.95 
2  1:50 1.40 15.48 42.28 
  1:100 1.43 10.67 39.37 
  1:200 1.54 8.17 35.28 
  1:400 1.54 4.68 35.15 
    
 Mean  1.48 9.75 38.02 
 SD  0.07 4.54 3.45 
 CV  4.84 46.58 9.08 
 
Table 1.  Influence of sample dilution on the avidity parameters. Two serum samples of 
different avidities were tested in different dilutions, all of which, however, gave ODs in 
the linear part of the standard curve. Results are given individually and as mean, SD and 
variation coefficient (CV = (SD/mean) * 100) for each of the samples. Variation was 
small for the AI and the percentage of high avidity antibodies, whereas it was higher for 
the percentage of low avidity antibodies. 
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 AI [M] Low avidity antibody
(% of total)
High avidity antibody 
(% of total) 
Mean 3.43 6.46 61.75 
SD 0.16 4.98 5.85 
CV 4.78 77.16 9.47 
 
Table 2. Reproducibility of the avidity assay. A high avidity control serum was included 
in each of the 36 plates tested on 5 different days. Overall reproducibility degree was 
high for AI and for percentage of high avidity antibodies, and lower for percentage of low 
avidity antibodies. Weighted average intra-day variability was comparable (not shown). 
 
   30
Avidity index of TT-specific IgG 1 
antibodies and age
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Figure 2. Avidity index (AI) of TT-specific IgG1 antibodies in relation to age. The AIs of 
90 serum samples of apparently healthy children were plotted against age. The AI 
increases with growing age reflecting avidity maturation of TT specific antibodies of the 
IgG1 subclass during childhood. The AI is associated with log10(age) (p<0.0001), this 
association is approximated by the function AI[M] = [2.3324 + 
0.6989*log10(age[years])] (shown as a continuous curve). AI values of >3 M were 
arbitrarily assigned the value of 3 M (already before statistical analysis). 
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High avidity TT-specific IgG 1 
antibodies and age
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Figure 3. Fraction of high avidity IgG1 antibodies specific for TT in relation to age. The 
high avidity fractions (i.e. not eluted at NH4SCN concentrations up to 3 M) were plotted 
against age. In accordance with the AI increase with growing age, the high avidity 
fraction increases as well. The percentage of high avidity antibody is associated with 
log10(age) (p<0.0001), which is approximated by the equation: (% high avidity 
antibodies) = 30.203 + 23.551*log10(age[years]). 
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Low avidity TT-specific IgG 1 
antibodies and age
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Figure 4. Fraction of low avidity IgG1 antibodies specific for TT in relation to  age. The 
low avidity fractions (i.e. eluted at NH4SCN concentrations < 1 M) were plotted against 
age. In accordance with the high avidity fraction increase, the low avidity fraction 
decreases with growing age. The percentage of low avidity antibody is associated with 
exp(-age) (p<0.0001). The function approximating this relationship is: (% low avidity 
antibodies) = 9.3503 + 33.876*exp(-age). 
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Avidity index of TT-specific IgG1 
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Figure 5. Comparison of the avidity of TT-specific IgG1 antibodies  with the serum levels 
of TT-specific IgG antibodies. No statistically significant correlation was found between 
antibody avidity and antibody serum levels (p=0.19). 
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4 Discussion 
We adapted an isothiocyanate elution assay previously described and validated for 
other antigens (Goldblatt 1997) to measure the avidity of IgG1 antibodies directed against 
tetanus toxoid (TT) by assessing and - where indicated - optimizing several parameters, 
such as duration of incubation with NH4SCN, resistance of the antigen used for coating to 
NH4SCN, and dilution of serum samples. These optimization/validation steps were all 
successful, allowing to apply the assay to serum samples of 90 apparently healthy 
children aged between 5 months and 15 years with known TT immunization history. The 
objective of this cross-sectional study was to describe avidity maturation by assessing 
avidity distribution of TT-specific IgG1 antibodies in children of different ages.  
Avidity of IgG1 TT antibodies was found to increase with age. A direct 
correlation was observed between avidity index and log10(age). The avidity increase was 
most marked during the first five years of life. Whereas for most children younger than 1 
year AI was in the range of 1.5 - 2.5 M, for all children aged 4 years and more, the AI lay 
above 2.5 M. After about 5 years, the AI seems to reach a plateau around 3 M. The rise of 
the high-avidity antibody fraction (i.e. not eluted at NH4SCN concentrations up to 3 M) 
with increasing age is in accordance with the rising AI. A statistically significant 
correlation between the percentage of high avidity antibodies and log10(age) could be 
detected as well.  It also seems to reach a plateau around 5 years. The percentage of low 
avidity  antibodies decreases with age, it was found correlated with exp(-age). Two 
samples showed a significantly lower AI than samples of other children of comparable 
age. One child, displaying an AI of 1.17 at 2.2 years was found to have received an 
incomplete (i.e. 2 doses) and delayed (i.e. at 11 and 12 months) course of primo-
vaccination, which probably explains the low value. For another child with a low AI of 
2.1 at 3.8 years, no explanation could be found. No correlation could be found between 
avidity and TT-specific total IgG levels. 
4.1 Potentially confounding factors 
We examined serum samples of children who were evaluated to rule out an 
immunodeficiency, i.e. who may not be fully representative for a population of healthy 
children. However, the presence of such a deficiency seems highly improbable in 
children mounting an strong antibody response to TT immunization (titers >1000 
mUI/ml), so that we considered them as apparently healthy. This assumption is further 
supported by the fact that the method developed during this thesis project was 
subsequently used in a longitudinal follow-up study to assess the avidity of TT-specific 
IgG1 antibodies in 400 Gambian children at 5 and at 12 months of age. AIs (1.56 ± 0.34 
M and 2.28 ± 0.30 M at 5 and 12 months of age, respectively) and percentages of high 
and of low avidity antibodies were comparable with the results obtained in our population 
(Schlegel-Haueter S et al., manuscript in preparation).  
Our avidity assessment was restricted to IgG1, whereas the serum levels were 
assessed for total IgG. Since TT-specific IgG antibodies are mainly of the IgG1 isotype 
(Devey 1985, Kroon 1999, Aboud 2001), and since a very close correlation between TT-
specific IgG and IgG1 levels has been observed in our samples (not shown), it can be 
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safely assumed that the IgG1 fraction makes up almost the entire IgG population and is 
therefore representative for the total IgG fraction. The chemical stability of the coating 
antigen not being guaranteed at NH4SCN concentrations above 3 M, we decided not to 
assess AIs above this value. With this restriction some AIs might be underestimated, as 
some samples, especially of adults (not shown), seem to have AIs slightly above 3 M. 
Further experiments may be indicated to assess the stability of the antigen at conditions 
closer to those of our assay, i.e. in presence of serum. In any case, this theoretical concern 
does not affect the main observation of a very prolonged maturation period, extending 
over 5 years. The lower limit of TT-specific IgG antibody levels at 1000 mIU/mL as an 
inclusion criteria, used in this study to rule out immunodeficiency, may probably be 
unnecessarily high with respect to applicability of the assay. Further experiments would 
be indicated in order to determine the lower limit above which the assay works reliably. 
This would allow evaluation of the avidity of TT antibodies in patients with suboptimal 
or weak TT-specific responses. 
4.2 Comparison with other reports on the avidity of TT-specific antibodies  
A general problem for the comparison of avidity studies is the plethora of 
different techniques of measuring avidity and the different definitions of AI and high and 
low avidities. Some authors only use one fixed concentration of the eluting agent and 
define the AI as ratio of optical density of the well with and without eluting agent 
(Abacioglu 1995). Others define the AI as concentration of eluting agent required to 
reduce the optical density by 50% (Avanzini 1998), which may yield different results 
than measuring reduction of antibody concentration, as soon as values lie outside the 
linear part of the standard curve.  
A cross-sectional study on levels and avidity of IgG antibodies to TT in 138 
Tanzanian children aged 1-15 years reported that in 1-5 year-old children, 89% had a 
high AI, whereas among 6-15 year-old children only 52% had a high AI. (Aboud 2000).  
In this study, high and low AIs were defined as a ratio of optical density of the wells with 
and without eluting agent (i.e. urea) of >50% and <30% respectively. This apparent 
contradiction to our results, i.e. a reduction of antibody avidity with age, may be 
explained by several differences in methodology. Whereas we only considered serum 
samples with TT-specific IgG levels of ≥ 1000 mIU/mL, this group also included samples 
with antibody levels considered as unprotective, i.e. below 100 mIU/mL, which may rise 
questions regarding the quality of avidity values apparently not validated at such low 
serum levels. They indeed found a strong association between low AI and non-protective 
antibody level in multivariate logistic regression analysis. This might be at least partially 
explained by unsuccessful priming, administration of insufficient number of vaccine 
doses, or failure to detect small amounts of high-avidity antibodies.  Indeed, their 
immunization schedule differed from ours in that the third DPT vaccine dose was given 
already by the 12th week of life, while a booster during childhood was not scheduled in a 
standardized way. Moreover, for children between 6 and 15 years of age, documentation 
of immunization was frequently missing. This might as well introduce a certain bias, as 
e.g. the same group showed in another study in adult Tanzanian women that TT-specific 
IgG levels were significantly higher in women presenting written documentation of 
immunization compared to women with oral history of immunization only (Aboud 2001). 
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A further factor to complicate comparability between the two studies is the application of 
a different assay (elution assay with urea at one single concentration, different definitions 
of AI and high avidity [see above]).  
TT-specific antibody avidity has been assessed in other contexts as well. One 
study tested sera of mother-infant pairs at birth and found that TT immunization during 
pregnancy resulted in higher anti-TT IgG levels without affecting the avidity (Abacioglu 
1995). These results are in accordance with the concept of an already matured immune 
response resulting from previous immunization. The study found no significant 
differences in AIs within the mother-infant pairs. Another group found significantly 
higher IgG AIs in infants compared to those of their mothers in a small group of mother-
infant pairs. This was independent of putative antigen load, and no correlation was found 
between antibody level and avidity. Antibody concentrations had a tendency to be higher 
in infants than in their mothers. The authors postulate a preferential transplacental 
transfer of high avidity antibodies (Avanzini 1998). 
Affinity of TT-specific antibodies was shown to be lower in protein-energy 
malnourished children than in healthy controls (Chandra 1984). A small study assessing 
affinity of TT-specific antibodies in freshly immunized adults showed failure of affinity 
maturation in patients with rheumatoid arthritis, whereas adults with systemic lupus 
erythematosus and healthy controls showed increase of affinity (Devey 1987). Whereas 
patients with AIDS showed a reduced quantitative antibody response to TT immunization 
recall, affinity of TT-specific IgG was found equally high as in controls (Janoff 1991). 
Similar results were obtained with avidity of TT-specific IgG1 antibodies (Kroon 1999). 
4.3 Kinetics of avidity maturation of TT-specific antibodies in children 
Our results show a prolonged avidity maturation period of TT-specific IgG1 
antibodies during childhood. This raises two interesting issues: First, the duration of 
avidity maturation during an immune response (Berek 1999). As far as antibodies to TT 
are concerned, its extension over several years of age clearly demonstrates that although 
germinal centers are needed to initiate somatic hypermutation, B-cell competition and 
clonal selection, i.e. initiate avidity maturation, this process extends well beyond the few 
weeks during which germinal centers are observed. The existence of a post-germinal 
center compartment in which affinity maturation takes place has indeed be postulated in 
mice (Smith 2000), and our observations suggest that it may exist in humans as well. It 
will be of interest to try to understand the factors defining whether avidity maturation is 
essentially completed within a few months (such as following hepatitis B immunization, 
[Siegrist CA et al., manuscript in preparation]) or extends for several years. Persistence of 
antigen, either at the site of injection or at the surface of follicular dendritic cells, could 
play an important role. 
The second interesting issue is that of immune system maturation during 
childhood (Ridings 1997, Ridings 1998, Siegrist 2001). As all of the children in our study 
were immunized at about the same age, it is not possible to give a clear answer to the 
question whether the observed rise in avidity was due to the maturation of the immune 
system during the first years of life or rather to the inherent duration of an avidity 
maturation of an immune response to a vaccine. Data on avidity maturation of TT-
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specific antibody in humans who were primo-vaccinated as adults is scarce. One healthy 
adult woman showed antibodies of a high AI (>3 M) within the first year after primo-
immunisation, suggesting faster avidity maturation than following infant immunization 
(data not shown). Repeated measurements of anti-rubella antibody avidity in formerly 
non-immune primo-vaccinated adult women seemed to show an equally fast maturation 
within weeks (Pullen 1986). Thus, the low average avidity values in young children 
might reflect the immaturity of their B-cell immune responses rather than a normal, age-
independent slow rate of avidity maturation during years. This could be related to factors 
limiting the development of germinal centers in early life, as recently observed in infant 
mice (Pihlgren M et al., manuscript submitted). Interestingly, this limitation of germinal 
center induction in infant mice is associated with a limitation of avidity maturation of 
antibody responses to small peptides or haptens, whereas responses to more complex 
protein antigens (pertussis toxin, tetanus toxoid) were similar to those in adults, although 
requiring several months for maturation (Schallert 2002). 
4.4 Avidity testing in clinical medicine 
Measuring avidity is more and more appreciated as an important tool in clinical 
medicine, be it in diagnosis of infection or in assessment of new vaccines or 
immunisation responses of immunocompromized patients. For instance, in the presence 
of immunoglobulins, avidity determination was able to distinguish between acute and 
past (respectively primary and non-primary) infections from rubella (Hedman 1988), 
toxoplasma (Hedman 1989), cytomegalovirus (Bodeus 1998, Bodeus 1999), or Epstein-
Barr virus (Schubert 1998). Such distinctions may be of primordial importance in the 
context of pregnancy or of immune suppression. Measuring avidity in human immune 
response can be important for the assessment of novel vaccine formulas, as for example 
different pneumococcal or Haemophilus influenzae type b conjugate vaccines were found 
to elicit different avidity responses (Schlesinger 1992, Anttila 1999b, Goldblatt 1998). 
Avidity can also serve as a surrogate for successful priming by induction of 
immunological memory. In infants with low Haemophilus influenzae type b-specific 
antibody following primary immunization with Haemophilus influenzae type b 
conjugated vaccines, antibody avidity after booster immunization was still low, indicating 
absence of priming (Goldblatt 1998). Antibody avidity has also been found to be a 
surrogate marker of priming after meningococcal conjugate vaccines (Joseph 2001). 
Assessment of priming is particularly important in patients at high risk for complicated 
infections, such as immunosuppressed patients after a bone marrow transplantation. 
When immune response to a standard pneumococcal polysaccharide vaccine was 
assessed in children who were immunized at different time points after bone marrow 
transplantation, an inadequate induction of serum antibody was not only found in terms 
of antibody level, but avidity declined significantly in the majority of patients and 
remained low for months, which seemed to suggest the need of alternative immunisation 
strategies in children after bone marrow transplantation (Spoulou 2000). Our own 
preliminary observations of avidity maturation of the immune response to TT in bone 
marrow transplanted adults seemed to reveal distinct patterns of avidity responses: in 
some patients high avidity antibodies could be found soon after the primary post-
transplantation immunisation, whereas others seemed to undergo an avidity maturation 
process similar to that of primo-vaccinated children (data not shown). The significance of 
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this phenomenon is not clear yet, but suggests persistence of memory cells, despite 
irradiation and chemotherapy, which are readily recalled by administration of a single 
vaccine dose after transplantation. 
A recent paper incriminated an avidity maturation defect in the pathogenesis of a 
subset of patients with common variable immunodeficiency (CIVD). They found a subset 
of patients, clinically characterized by a later onset of the disease, which showed 
significantly lower frequency of somatic mutations in a V gene region of circulating B-
cells. Further on, there was neither evidence for an abnormal selection process nor for a 
quantitative functional defect of the hypermutation machinery (i.e. mutation rate in the 
non-immunoglobulin BCL-6 gene was not diminished in these patients) and therefore 
suggested a defect of targeting of the hypermutation machinery as possible characteristic 
of such patients (Bonhomme 2000). It may thus also be of high interest to investigate the 
role of avidity maturation in immunodeficiency syndromes and the utility of relatively 
simple avidity assays as diagnostic tools.  
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